NIOPEG DIN 02546973
Status: Marketed
Holder: NORA PHARMA INC
Health Canada record
| Active ingredient(s) | PEGFILGRASTIM 6 MG |
|---|
| Dosage form | Solution |
|---|
| Route | Subcutaneous |
|---|
| Schedule | SCHEDULE D; PRESCRIPTION |
|---|
| Class | Human |
|---|
| ATC | L03AA13 PEGFILGRASTIM |
|---|
| Original market date | 12-Feb-2025 |
|---|
| Current status date | 12-Feb-2025 |
|---|
| Source | Health Canada DPD |
|---|
Establishment licence of the holder
Nora Pharma Inc — licence 3-002506, currently licensed, last inspection rating C (2022-11-29).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing PEGFILGRASTIM
| DIN | Product | Company | Form | Strength | Status |
|---|
| 02550857 | ARMLUPEG | LUPIN PHARMA CANADA LIMITED | Solution | PEGFILGRASTIM 6 MG | Approved |
| 02564394 | DYRUPEG | CURATEQ BIOLOGICS PRIVATE LIMITED | Solution | PEGFILGRASTIM 6 MG | Approved |
| 02484153 | FULPHILA | BIOCON BIOLOGICS CANADA INC | Solution | PEGFILGRASTIM 10 MG | Marketed |
| 02529343 | LAPELGA | APOTEX INC | Solution | PEGFILGRASTIM 6 MG | Marketed |
| 02474565 | LAPELGA | APOTEX INC | Solution | PEGFILGRASTIM 6 MG | Marketed |
| 02249790 | NEULASTA | AMGEN CANADA INC | Solution | PEGFILGRASTIM 10 MG | Marketed |
| 02506238 | NYVEPRIA | PFIZER CANADA ULC | Solution | PEGFILGRASTIM 6 MG | Marketed |
| 02553945 | PEXEGRA | JAMP PHARMA CORPORATION | Solution | PEGFILGRASTIM 10 MG | Marketed |
| 02497395 | ZIEXTENZO | SANDOZ CANADA INCORPORATED | Solution | PEGFILGRASTIM 6 MG | Marketed |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|
| 33095 | 2024-04-17 | New Drug Submission (NDS) | |
Request a quote for NIOPEG
How to read a Canadian DIN record